Free Trial

Abpro (ABP) Competitors

Abpro logo
$0.27 +0.01 (+5.72%)
As of 08/15/2025 04:00 PM Eastern

ABP vs. DRRX, CUE, LTRN, ICCC, HOWL, ANL, TELO, ABVC, PYRGF, and DTIL

Should you be buying Abpro stock or one of its competitors? The main competitors of Abpro include DURECT (DRRX), Cue Biopharma (CUE), Lantern Pharma (LTRN), ImmuCell (ICCC), Werewolf Therapeutics (HOWL), Adlai Nortye (ANL), Telomir Pharmaceuticals (TELO), ABVC BioPharma (ABVC), PyroGenesis Canada (PYRGF), and Precision BioSciences (DTIL). These companies are all part of the "pharmaceutical products" industry.

Abpro vs. Its Competitors

Abpro (NASDAQ:ABP) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Abpro has a net margin of 0.00% compared to DURECT's net margin of -96.19%. Abpro's return on equity of 0.00% beat DURECT's return on equity.

Company Net Margins Return on Equity Return on Assets
AbproN/A N/A -241.16%
DURECT -96.19%-259.16%-71.78%

Abpro currently has a consensus price target of $4.00, indicating a potential upside of 1,403.76%. Given Abpro's stronger consensus rating and higher possible upside, equities analysts plainly believe Abpro is more favorable than DURECT.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abpro
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
DURECT
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

23.3% of Abpro shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 20.8% of Abpro shares are held by company insiders. Comparatively, 3.2% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Abpro has higher earnings, but lower revenue than DURECT.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abpro$180K89.83-$7.23MN/AN/A
DURECT$2.03M29.21-$8.32M-$0.10-19.10

In the previous week, DURECT had 8 more articles in the media than Abpro. MarketBeat recorded 10 mentions for DURECT and 2 mentions for Abpro. Abpro's average media sentiment score of 1.63 beat DURECT's score of 0.53 indicating that Abpro is being referred to more favorably in the media.

Company Overall Sentiment
Abpro Very Positive
DURECT Positive

Abpro has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Summary

Abpro beats DURECT on 9 of the 14 factors compared between the two stocks.

Get Abpro News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABP vs. The Competition

MetricAbproMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.29M$3.10B$5.68B$9.81B
Dividend YieldN/A2.23%3.79%4.11%
P/E RatioN/A20.8931.0825.11
Price / Sales89.83364.47466.21115.16
Price / CashN/A42.3037.4059.05
Price / Book-0.958.659.096.18
Net Income-$7.23M-$54.65M$3.26B$265.11M
7 Day Performance8.13%6.56%7.36%4.21%
1 Month Performance21.91%7.53%5.47%2.01%
1 Year PerformanceN/A13.69%30.61%23.74%

Abpro Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABP
Abpro
N/A$0.27
+5.7%
$4.00
+1,403.8%
N/A$15.29M$180K0.0015Positive News
Earnings Report
DRRX
DURECT
1.8474 of 5 stars
$1.85
-0.5%
N/A+66.1%$57.74M$2.03M-12.3380Earnings Report
Short Interest ↓
CUE
Cue Biopharma
4.5083 of 5 stars
$0.84
+10.0%
$4.00
+377.3%
+39.1%$57.42M$9.29M-1.2560Earnings Report
Gap Up
LTRN
Lantern Pharma
2.9376 of 5 stars
$5.20
-2.3%
$25.00
+380.8%
+6.5%$57.38MN/A-2.8320Earnings Report
Gap Up
ICCC
ImmuCell
0.5395 of 5 stars
$6.17
-1.1%
N/A+65.3%$56.44M$26.49M-88.1370News Coverage
Earnings Report
Short Interest ↓
HOWL
Werewolf Therapeutics
3.7249 of 5 stars
$1.21
-2.4%
$8.33
+588.7%
-34.2%$55.64M$1.88M-0.7240News Coverage
Earnings Report
Analyst Revision
ANL
Adlai Nortye
1.3663 of 5 stars
$1.50
flat
$9.00
+500.0%
-44.9%$55.35M$5M0.00127Short Interest ↑
Gap Up
TELO
Telomir Pharmaceuticals
2.6173 of 5 stars
$1.83
flat
$15.00
+719.7%
-63.2%$54.47MN/A-4.361Earnings Report
Gap Down
ABVC
ABVC BioPharma
0.4019 of 5 stars
$3.00
-6.3%
N/A+364.1%$54.34M$510K-23.0830News Coverage
Earnings Report
PYRGF
PyroGenesis Canada
N/A$0.29
-1.5%
N/A-58.3%$53.72M$9.14M-4.7890Gap Up
DTIL
Precision BioSciences
4.1248 of 5 stars
$4.86
+0.4%
$47.00
+867.1%
-45.3%$53.67M$68.70M-2.42200News Coverage
Positive News
Analyst Revision

Related Companies and Tools


This page (NASDAQ:ABP) was last updated on 8/16/2025 by MarketBeat.com Staff
From Our Partners